188 related articles for article (PubMed ID: 35460355)
21. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
[TBL] [Abstract][Full Text] [Related]
22. Prediction of MYCN Amplification, 1p and 11q Aberrations in Pediatric Neuroblastoma
Qian L; Yang S; Zhang S; Qin H; Wang W; Kan Y; Liu L; Li J; Zhang H; Yang J
Front Med (Lausanne); 2022; 9():840777. PubMed ID: 35372427
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
24. Prediction for Mitosis-Karyorrhexis Index Status of Pediatric Neuroblastoma via Machine Learning Based
Feng L; Qian L; Yang S; Ren Q; Zhang S; Qin H; Wang W; Wang C; Zhang H; Yang J
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204353
[TBL] [Abstract][Full Text] [Related]
25. Correlation Between
Santiago T; Tarek N; Boulos F; Hayes C; Jeha S; Raimondi S; Rodriguez-Galindo C
J Glob Oncol; 2019 Jul; 5():1-7. PubMed ID: 31365300
[TBL] [Abstract][Full Text] [Related]
26. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
[TBL] [Abstract][Full Text] [Related]
27. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
28. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
29. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.
Su Y; Wang L; Zhao Q; Yue Z; Zhao W; Wang X; Duan C; Jin M; Zhang D; Chen S; Yin J; Qiu L; Cheng X; Xu Z; Ma X
Mol Oncol; 2020 Nov; 14(11):2884-2893. PubMed ID: 32896084
[TBL] [Abstract][Full Text] [Related]
30. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
31. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
[TBL] [Abstract][Full Text] [Related]
32. Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma.
Wang H; Wang X; Xu L; Zhang J; Cao H
BMC Pediatr; 2021 Jun; 21(1):272. PubMed ID: 34116676
[TBL] [Abstract][Full Text] [Related]
33. Identification of an Ultra-High-Risk Subgroup of Neuroblastoma Patients within the High-Risk Cohort Using a Computed Tomography-Based Radiomics Approach.
Wang H; Chen X; Li T; Xie M; Qin J; Zhang L; Ding H; He L
Acad Radiol; 2024 Apr; 31(4):1655-1665. PubMed ID: 37714717
[TBL] [Abstract][Full Text] [Related]
34. Direct Targeting of
Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
[TBL] [Abstract][Full Text] [Related]
35. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
[TBL] [Abstract][Full Text] [Related]
36. Genetic variation associated with childhood and adult stature and risk of MYCN-amplified neuroblastoma.
Semmes EC; Shen E; Cohen JL; Zhang C; Wei Q; Hurst JH; Walsh KM
Cancer Med; 2020 Nov; 9(21):8216-8225. PubMed ID: 32945147
[TBL] [Abstract][Full Text] [Related]
37. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
[TBL] [Abstract][Full Text] [Related]
38. MYCN protein stability is a better prognostic indicator in neuroblastoma.
Yang Y; Zhao J; Zhang Y; Feng T; Yv B; Wang J; Gao Y; Yin M; Tang J; Li Y
BMC Pediatr; 2022 Jul; 22(1):404. PubMed ID: 35820898
[TBL] [Abstract][Full Text] [Related]
39. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
